|
|
|
|
|
SAN DIEGO, Feb 19, 2020 - (ACN Newswire) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS @ Shanghai, announced today that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*. Under terms of the agreement, the Lung Cancer Initiative has taken an exclusive license to research, develop and commercialize novel molecules from within the DNX portfolio. Financial terms of the collaboration were not disclosed.
"We are delighted to be collaborating with the Lung Cancer Initiative at Johnson & Johnson," said Rajiv Datar, Ph.D., co-founder and CEO of DNX. "We look forward to progressing DNX's novel molecules into clinical development."
"Our collaboration with the Lung Cancer Initiative at Johnson & Johnson was fostered by being an awardee of the Lung Cancer Innovation QuickFire Challenge and receiving residency at Johnson & Johnson Innovation - JLABS @ Shanghai," commented Dr. Carl Edwards III, CSO of DNX. "We are now looking forward to establishing our Asia-Pacific Research and Development capabilities in Shanghai, which will be wholly dedicated to Cancer Immunotherapy."
About DNX Biopharmaceuticals, Inc.
Founded in 2014 and headquartered in San Diego, California, USA, DNX is a biopharmaceutical company developing non-immunogenic, long-acting biologic therapies for the treatment of patients with life-long diseases linked to inflammation, autoinflammation and oncology. As an awardee of the Lung Cancer Innovation QuickFire Challenge, DNX received residency at Johnson & Johnson Innovation - JLABS @ Shanghai. At JLABS Shanghai, DNX will pursue an ongoing R&D effort that leverages its intrinsically disordered protein technologies designed to explore the tumor microenvironment, leading to the identification of novel pathways that can be targeted with molecules to substantially influence "anti-tumoral" therapeutic responses. Ongoing nonclinical efforts have identified several novel candidates that may act as "Immune Checkpoint Inhibitors" alone or in combination with existing standard of care anti-PD-1 and CTLA-4 therapies to reverse CD8+ T cell functions, all with the aim of improving clinical outcomes across the vast range of cancer conditions. For more information, please visit www.dnxbio.com.
*Johnson & Johnson Enterprise Innovation Inc. is the legal entity to the agreement.
Media Contact:
Claude Gingras, CFO
Claude.Gingras@dnxbio.com
Related Links
- J&J Announcement of the Winners of the Lung Cancer QuickFire Award
https://www.newsfilecorp.com/redirect/XmpnIyDP
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52493
Topic: Press release summary
Source: DNX Biopharmaceuticals
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment 
Thursday, January 29, 2026 3:03:00 PM
|
|
|
Standard Chartered GBA Business Confidence Indices reveal steady business sentiment amid persistent external uncertainties
Jan 29, 2026 12:14 HKT/SGT
|
|
|
Quam Plus Financial Proudly Serves as Gold Sponsor to Capital Markets Forum 2026
Jan 29, 2026 11:52 HKT/SGT
|
|
|
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Thursday, January 29, 2026 9:14:00 AM
|
|
|
TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Wednesday, January 28, 2026 9:00:00 PM
|
|
|
Hong Kong Capital Markets Forum 2026 'Capturing Next Growth Momentum' Concludes Successfully
Jan 28, 2026 19:09 HKT/SGT
|
|
|
Nissin Foods (Hong Kong) Charity Fund Supporting Talents in Food and Nutritional Sciences for the Fourth Consecutive Year
Jan 28, 2026 18:40 HKT/SGT
|
|
|
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Wednesday, January 28, 2026 5:29:00 PM
|
|
|
MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Wednesday, January 28, 2026 5:08:00 PM
|
|
|
Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Wednesday, January 28, 2026 4:58:00 PM
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
